FindTrial
Sign In

Sulfonylureas

DRUG5 trials

Sponsors

Eli Lilly and Company, Canadian Network for Observational Drug Effect Studies, CNODES, Janssen Research & Development, LLC

Conditions

Diabetes Mellitus, Type 2Type 2 Diabetes Mellitus

Phase 3

A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus
CompletedNCT01648582
Eli Lilly and CompanyType 2 Diabetes Mellitus
Start: 2012-07-31End: 2014-12-31Updated: 2019-09-18

Unknown Phase

Incretin-based Drugs and the Risk of Heart Failure
CompletedNCT02456428
Canadian Network for Observational Drug Effect Studies, CNODESType 2 Diabetes Mellitus
Start: 2014-03-31End: 2015-05-31Updated: 2016-04-19
Incretin-based Drugs and Pancreatic Cancer
CompletedNCT02475499
Canadian Network for Observational Drug Effect Studies, CNODESDiabetes Mellitus, Type 2
Start: 2014-03-31End: 2015-04-30Updated: 2016-03-14
Incretin-based Drugs and Acute Pancreatitis
CompletedNCT02476760
Canadian Network for Observational Drug Effect Studies, CNODESDiabetes Mellitus, Type 2
Start: 2014-03-31End: 2015-04-30Updated: 2016-11-03
Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)
CompletedNCT03249506
Janssen Research & Development, LLCDiabetes Mellitus, Type 2
Start: 2016-05-12End: 2017-11-01Updated: 2017-11-21

Related Papers

Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors.
2021-08-282 citations
Effects of GLP‐1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52‐Week Clinical Study
BioMed Research International2021-01-0168 citations
Efficacy and Safety of Once Weekly Dulaglutide in East Asian Patients with Type 2 Diabetes: Subgroup Analysis by Potential Influential Factors.
2020-11-082 citations
Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies
Diabetes Therapy2020-08-284 citations
Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials
Diabetes Therapy2020-07-045 citations
Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis
Diabetes Therapy2020-04-109 citations
The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus
BioMed Research International2019-12-2520 citations
Achieving the composite end‐point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once‐weekly dulaglutide in Chinese patients with type 2 diabetes: A post‐hoc analysis
Journal of Diabetes Investigation2019-11-233 citations
Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2).
2019-06-2113 citations
2313-PUB: Efficacy by Baseline BMI with Once Weekly Dulaglutide in Chinese T2DM Patients
Diabetes2019-06-011 citations
A Multicenter Observational Study of Incretin-based Drugs and Heart Failure
New England Journal of Medicine2016-03-23220 citations